Suppr超能文献

药物中潜在的杂质:20 种合成试剂和副产物的特定化合物毒理学限度,以及烷基溴化物的特定类别毒理学限度。

Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides.

机构信息

Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.

MRL, Merck & Co., Inc., W 45-316, West Point, PA, USA.

出版信息

Regul Toxicol Pharmacol. 2018 Apr;94:172-182. doi: 10.1016/j.yrtph.2018.02.001. Epub 2018 Feb 9.

Abstract

This paper provides compound-specific toxicology limits for 20 widely used synthetic reagents and common by-products that are potential impurities in drug substances. In addition, a 15 μg/day class-specific limit was developed for monofunctional alkyl bromides, aligning this with the class-specific limit previously defined for monofunctional alkyl chlorides. Both the compound- and class-specific toxicology limits assume a lifetime chronic exposure for the general population (including sensitive subpopulations) by all routes of exposure for pharmaceuticals. Inhalation-specific toxicology limits were also derived for acrolein, formaldehyde, and methyl bromide because of their localized toxicity via that route. Mode of action was an important consideration for a compound-specific toxicology limit. Acceptable intake (AI) calculations for certain mutagenic carcinogens assumed a linear dose-response for tumor induction, and permissible daily exposure (PDE) determination assumed a non-linear dose-response. Several compounds evaluated have been previously incorrectly assumed to be mutagenic, or to be mutagenic carcinogens, but the evidence reported here for such compounds indicates a lack of mutagenicity, and a non-mutagenic mode of action for tumor induction. For non-mutagens with insufficient data to develop a toxicology limit, the ICH Q3A qualification thresholds are recommended. The compound- and class-specific toxicology limits described here may be adjusted for an individual drug substance based on treatment duration, dosing schedule, severity of the disease and therapeutic indication.

摘要

本文为 20 种广泛使用的合成试剂和常见的药物杂质副产物提供了毒理学限定值。此外,还为单官能团溴代烷基制定了 15μg/天的类别特异性限量值,与之前为单官能团氯代烷基定义的类别特异性限量值保持一致。化合物和类别特异性毒理学限定值均假设一般人群(包括敏感亚群)通过所有给药途径对药物进行终生慢性暴露。由于这些物质通过吸入途径具有局部毒性,因此还推导了丙烯醛、甲醛和甲基溴化物的吸入特异性毒理学限定值。作用模式是化合物特异性毒理学限定值的重要考虑因素。某些致突变性致癌物质的可接受摄入量 (AI) 计算假设肿瘤诱导呈线性剂量反应,可允许每日暴露量 (PDE) 确定假设非线性剂量反应。评估的几种化合物以前被错误地假设为致突变剂,或为致突变性致癌剂,但这里报告的此类化合物的证据表明其缺乏致突变性,且肿瘤诱导的作用模式为非致突变性。对于没有足够数据制定毒理学限定值的非致突变剂,建议使用 ICH Q3A 资格阈值。这里描述的化合物和类别特异性毒理学限定值可以根据药物的治疗持续时间、给药方案、疾病严重程度和治疗指征进行调整。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验